Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for Tough-to-Treat blood pressure in kidney patients

NCT ID NCT06150924

Disease control Sponsor: Mineralys Therapeutics Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether adding the experimental drug lorundrostat to standard SGLT2 inhibitor therapy can lower blood pressure in adults with chronic kidney disease and albuminuria (protein in urine). Sixty participants received either lorundrostat or a placebo for four weeks, then switched. The study is complete, and results will show if the drug safely improves blood pressure control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lorundrostat (an aldosterone synthase inhibitor) taken as a pill once daily
What this could lead to
If successful, this could point toward a new add-on treatment to better control blood pressure and protect kidney function in people with chronic kidney disease.
What could go wrong
This is a small, early-phase trial with only 60 participants and short treatment periods. Results may not apply to everyone, and the drug may cause side effects or fail to show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

60 people

The number who actually took part.

Started

Dec 2023

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Major Inclusion Criteria: 1. At Screening, UACR of 200-5000 mg/g, inclusive, in first morning urine void 2. At Screening, eGFRs of ≥30 mL/min/1.73 m2 3. At Screening, AOBP SBP of 135-180 mmHg, inclusive 4. On a stable treatment with an ACEi or ARB for at least 2 months prior to Screening 5. At Screening, body mass index (BMI) of \>18 kg/m2 Major Exclusion Criteria: 1. Subjects with known hypersensitivity to lorundrostat or any of its respective excipients 2. Subjects with known hypersensitivity to dapagliflozin or any of its respective excipients (subjects beginning dapagliflozin only) 3. At Screening, serum potassium \>5.0 mmol/L 4. History of clinically significant hyponatremia within 1 year prior to Screening 5. Use of epithelial sodium channel (ENaC) inhibitors or Mineralocorticoid receptor antagonist (MRAs), including, but not limited to amiloride, triamterene, spironolactone, eplerenone, finerenone, from 4 weeks prior to the Screening Visit and during study participation. With the exception of MRAs in primary aldosteronism 6. Medical history of kidney disease related to autoimmune diseases (lupus, anti-neutrophil cytoplasmic antibody \[ANCA\] vasculitis), multiple myeloma or other known paraproteins, infiltrative diseases of the kidney, obstructive nephropathy, cystic kidney diseases, and renal transplantation 7. Medical history of advanced liver disease, including cirrhosis 8. Medical history of active autoimmune disease or recent (within 30 days) or anticipated need for immunosuppressive therapy 9. Diabetes mellitus with a glycosylated hemoglobin (HbA1c) \>10% (\>86 mmol/mol) at Screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Albuminuria chronic kidney disease chronic renal failure syndrome diabetic kidney disease hypertensive disorder proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease

Contacts and locations

Locations

  • Academic Medical Research Institute (AMRI) - Los Angeles

    Los Angeles, California, 90022, United States

  • American Clinical Trials Llc

    Acworth, Georgia, 30101, United States

  • Amicis Research Center

    Northridge, California, 91324, United States

  • Amicis Research Center - Granada Hills

    Granada Hills, California, 91344, United States

  • Amicis Research Center - Vacaville

    Vacaville, California, 95687-3560, United States

  • Arizona Kidney Disease & Hypertension Centers (AKDHC) - Thomas Office

    Phoenix, Arizona, 85016, United States

  • Arizona Kidney Disease & Hypertension Centers (AKDHC) - Thunderbird Office

    Glendale, Arizona, 85306, United States

  • Balboa Nephrology Medical Group, Inc. (BNMG) - California Institute of Renal Research (CIRR) - Chula Vista

    Chula Vista, California, 91910, United States

  • Balboa Nephrology Medical Group, Inc. (BNMG) - El Centro

    El Centro, California, 92243, United States

  • Balboa Nephrology Medical Group, Inc. (Bnmg) - La Mesa

    La Mesa, California, 91942-3059, United States

  • Chrysalis Clinical Research (CCR)

    St. George, Utah, 84790, United States

  • ClinCept, LLC

    Columbus, Georgia, 32896, United States

  • Colorado Kidney Care (Denver Nephrology) - Denver Office

    Denver, Colorado, 80218-1216, United States

  • Columbia Nephrology

    Columbia, South Carolina, 29203, United States

  • Dallas Nephrology Associates (Dna) - Renal Disease Research Institute (Rdri)

    Dallas, Texas, 75235, United States

  • E T Nephrology Associates - Lufkin

    Lufkin, Texas, 75904, United States

  • Elixia Central Florida, LLC

    Orlando, Florida, 32806, United States

  • Elixia MKC, LLC

    Pontiac, Michigan, 48341, United States

  • Elixia Pines, LLC

    Hollywood, Florida, 33024, United States

  • Gamma Medical Research, Inc

    Mission, Texas, 78572, United States

  • Genesis Clinical Research - Tampa

    Tampa, Florida, 33614, United States

  • Georgia Nephrology, Llc

    Lawrenceville, Georgia, 30046-8761, United States

  • Indago Research and Health Center

    Hialeah, Florida, 33012, United States

  • Infigo Clinical Research, Llc

    Sanford, Florida, 32771, United States

  • Kansas City Kidney Consultants (Arms, Dodge, Robinson, Wilber & Crouch, Inc.) - Kansas City

    Kansas City, Missouri, 64111, United States

  • Lcms Health University Medical Center New Orleans

    New Orleans, Louisiana, 70112-3018, United States

  • Liberty Research Center

    Dallas, Texas, 75237, United States

  • Mendez Center for Clinical Research, LLC

    Woodbridge, Virginia, 22191, United States

  • Nephrology Associates

    Fresh Meadows, New York, 11365, United States

  • Nephrology Associates of Kentuckiana, PSC (NAK)

    Louisville, Kentucky, 40205, United States

  • Nephrology Associates, PC

    Fresh Meadows, New York, 11365, United States

  • Nephrology Associates, Pllc - Winston-Salem

    Winston-Salem, North Carolina, 27103, United States

  • Nephrology Consultants - Oklahoma City

    Oklahoma City, Oklahoma, 73116-1516, United States

  • Nephrology of the Golden Isles - Brunswick

    Brunswick, Georgia, 31520, United States

  • Northwest Louisiana Nephrology, Llc - Shreveport

    Shreveport, Louisiana, 71101, United States

  • Palm Beach Diabetes and Endocrine Specialists, PA (PBDES) - West Palm Beach Office

    West Palm Beach, Florida, 33401, United States

  • Prx Research

    Mesquite, Texas, 75149, United States

  • Qway Research

    Coconut Grove, Florida, 33133, United States

  • R&H Clinical Research

    Katy, Texas, 27205, United States

  • Seacoast Kidney & Hypertension Specialists - Portsmouth Office

    Portsmouth, New Hampshire, 03801, United States

  • Southeast Renal Research Institute

    Chattanooga, Tennessee, 37408, United States

  • Suny Downstate Medical Center - Parkside Dialysis Center

    Brooklyn, New York, 11226-1508, United States

  • Triad Internal Medicine

    Asheboro, North Carolina, 27205, United States

  • Tufts University School of Medicine (Tusm) - Tufts Medical Center (Tmc) (Tufts-New England Medical Center)

    Boston, Massachusetts, 02111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.